Advanced Search

 

Study ID Status Title Patient Level Data
HYT109091 Completed A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in combination with Pazopanib in Subjects with Advanced Solid Tumors
HZA102928 Completed A randomised, double blind, placebo controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled GW685698X containing magnesium stearate in healthy subjects Study Listed on ClinicalStudyDataRequest.com
HZA102940 Completed A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy japanese subjects Study Listed on ClinicalStudyDataRequest.com
HZA105871 Completed A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects Study Listed on ClinicalStudyDataRequest.com
HZA108799 Completed A randomised, double blind, two-way crossover study, to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single inhaled administration of GW685698X (800 mcg) with and without magnesium stearate, in mild/moderate asthmatic patients. Study Listed on ClinicalStudyDataRequest.com
HZA109895 Terminated An exploratory study to evaluate the response of salmeterol plus fluticasone vs fluticasone alone to experimental nasal inoculation with rhinovirus Study Listed on ClinicalStudyDataRequest.com
HZA109912 Completed A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval Study Listed on ClinicalStudyDataRequest.com
HZC111348 Completed Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
I13105054 Completed A dose-escalating study of the safety and pharmacokinetics of GSK679586A in healthy volunteers and mild asthmatics.
IBN104125 Completed A multi centre, randomised, open label, cross-over study to evaluate the percentage of false negative osteoporosis diagnosis’s using the standard case-finding procedure as described by the Dutch Institute for Healthcare (CBO) and to determine the preference of adult osteoporosis patients between once monthly dosing of ibandronate (150 mg) and once weekly dosing of alendronate (70 mg)
IDB-200-001 Completed A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine with reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in subjects between 18-60 and Over 60 Years of Age. Study Listed on ClinicalStudyDataRequest.com
IGZ111452 Terminated A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1247303 in Healthy Male and Female Subjects
ILI105618 Completed A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients with B Cell Non-Hodgkin'sLymphoma" Study Listed on ClinicalStudyDataRequest.com
ILI108621 Completed A phase I, dose escalation study to assess the safety & biological activity of Interleukin 18 (SB-485232) administered by IV infusion in combination with pegylated liposomal doxorubicin (Doxil) in advanced stage epithelial ovarian cancer Study Listed on ClinicalStudyDataRequest.com
IND 001/2008 Completed A double blind randomized controlled trial in school going children, to evaluate the impact of a multiple micronutrient fortified nutritional powder on physical performance measures
ING111207 Completed A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 in Healthy Subjects
ING111322 Completed GSK1349572 Repeat Dose Escalation Study
INO102141 Completed A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late asthmatic response in subjects with mild asthma.
IP2107882 Completed A single-centre, randomized, double-blind , placebo controlled, dose escalating cross-over study to evaluate the safety, tolerability and pharmacokinetics of single inhaled doses of GSK610677 and placebo in healthy male subjects
IPA101985 Completed A two-centre, randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with repeat doses of inhaled GSK256066 on the allergen-induced late asthmatic response in subjects with mild asthma
IPA106620 Completed A double blind, placebo controlled, repeat dose study to determine the effect of GSK256066 87.5 mcg to protect against AMP challenge in the lung in mild steroid-naive asthmatics.
IPA107948 Completed A randomized, double-blind, double-dummy, placebocontrolled,three-period, incomplete block, crossover study, to a investigate the effect of 14 days repeat inhaled dosing with GSK256066 in mild/moderate asthmatic patients.
IPC101939 Completed A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of inhaled GSK256066 in mild to moderate COPD patients
IPC103711 Completed A double blind, placebo controlled, repeat dose study to compare the effectiveness of two doses of GSK256066 with placebo in reducing lung inflammation following segmental LPS challenge in healthy volunteers
IPI100477 Completed A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD patients.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.